

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 19, 2002, 14:22:59 ; Search time 291.77 Seconds
(without alignments)
5137.150 Million cell updates/sec

Title: US-09-788-476a-3
Perfect score: 873
Sequence: 1 tggagtgaggggtaacaaga.....tgatatgtgtcgtgtaaat 873

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues
Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: N_Geneseq_032802.*
2: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
3: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
4: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
5: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
6: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
7: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
8: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
9: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
10: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
11: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
12: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
13: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
14: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
15: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
16: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
17: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
18: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
19: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
20: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
21: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
22: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
23: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2001.DAT.*
24: /SIDSL1/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	873	100.0	1071	22 AAC88100	Human FLEXHT-31 nu
2	873	100.0	1154	22 AAS29109	CDNA encoding for
3	853.4	97.8	891	21 AAS62602	CDNA sequence #389
4	465.6	53.3	471	21 AAC00738	Human secreted pro
5	334	38.3	408	22 AAH81555	Human differential
6	265.4	30.4	5469	22 AAI37635	Human musculoskele
7	265.4	30.4	5469	22 ABA08022	Human ovarian and
8	265.4	30.4	5469	22 AAL06683	Human reproductive
9	265.4	30.4	5469	22 AAK84119	Human immune/haema

C 10	265.4	30.4	9453	22 AAL37634	Human musculoskele
C 11	265.4	30.4	9453	22 ABA08021	Human ovarian and
C 12	265.4	30.4	9453	22 AAL06682	Human reproductive
C 13	265.4	30.4	9453	22 AAK84118	Human Immune/haema
C 14	258.6	29.6	266	20 AAV89379	EST clone CL152.
C 15	227.2	26.0	591	22 AAX85623	Novel CDNA sequenc
C 16	211.8	24.3	255	22 AAH82022	Rat differential t
C 17	55.4	6.3	1686	16 AOH87587	DNA encoding leuco
C 18	55	6.3	399	23 AAS90682	DNA encoding novel
C 19	55	6.3	399	23 AAS93406	DNA encoding novel
C 20	54	6.2	5659	24 ABL32375	Human immune syste
C 21	54	6.2	5659	24 ABL34487	Human metastasis a
C 22	53.6	6.1	591	23 AAS70521	DNA encoding novel
C 23	53.6	6.1	591	23 AAS70706	DNA encoding novel
C 24	53.6	6.1	591	23 AAS90721	DNA encoding novel
C 25	53.6	6.1	1416	23 AAS87163	DNA encoding novel
C 26	53.6	6.1	3211	18 AAT89346	Human p160 CDNA 16
C 27	53.6	6.1	3901	18 AAT89345	Human p160 CDNA 16
C 28	52.6	6.0	29392	19 AAV15422	Mouse poly Ig rece
C 29	52.2	6.0	2334	23 AAS90705	DNA encoding novel
C 30	52	6.0	510	23 AAS69539	DNA encoding novel
C 31	52	6.0	510	23 AAS71141	DNA encoding novel
C 32	52	6.0	510	23 AAS90687	DNA encoding novel
C 33	51.4	5.9	2187	23 AAS75468	DNA encoding novel
C 34	51.4	5.9	2347	23 AAS75464	DNA encoding novel
C 35	51.4	5.9	2482	23 AAS90736	DNA encoding novel
C 36	51.2	5.9	305	22 ABA48950	Human breast cell
C 37	51.2	5.9	305	22 ABA66871	Human foetal liver
C 38	51.2	5.9	305	22 ABA33942	Probe #12408 for g
C 39	51.2	5.9	305	22 ABA33906	Human brain expres
C 40	51.2	5.9	305	22 AAK1027	Human bone marrow
C 41	51.2	5.9	305	22 AAT21797	Probe #11730 for g
C 42	51.2	5.9	305	22 AAI70083	Probe #15769 used t
C 43	51.2	5.9	305	22 AAT07480	Probe #7471 used t
C 44	51.2	5.9	496	22 ABA43847	Human breast cell
C 45	51.2	5.9	496	22 ABA54309	Human foetal liver

ALIGNMENTS

RESULT 1	
AAC88100	standard; CDNA: 1071 BP.
ID	AAC88100
AC	AAC88100;
DT	09-MAR-2001 (first entry)
DE	Human FLEXHT-31 nucleotide sequence SEQ ID NO:86.
XX	Human, FLEXHT; full-length molecules expressed in human tissue;
XX	diagnosis; gene expression; genetic linkage; genetic variability;
XX	antianaemic; anticonvulsant; antiarteriosclerotic; immunomodulatory;
XX	cytostatic; antilastmatic; antinflammatory; hepatotropic; antidiabetic;
XX	anti-gout; antithyroid; neuroprotective; antiarthritic; osteoprotic;
XX	antiproliferic; antirheumatic; antitumor; gene therapy; anaemia; gout;
XX	epilepsy; arteriosclerosis; atherosclerosis; developmental disorder;
XX	cancer; immunological disorder; asthma; bronchitis; cirrhosis;
XX	Crohn's disease; diabetes mellitus; Grave's disease; multiple sclerosis;
XX	osteoarthritis; pancreatitis; rheumatoid arthritis; psoriasis;
XX	ulcerative colitis; ss.
OS	Homo sapiens.
XX	
PN	WO200070047-A2.
XX	
PD	23-NOV-2000.
XX	
PF	12-MAY-2000; 2000WO-US13299.
XX	
PR	14-MAY-1999; 99US-0311894.
PR	14-MAY-1999; 99US-0311937.

PR 14-MAY-1999; 99US-0311940.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Yue H, Tang YT, Lal P, Reddy R, Batta S, Baughn MR, Yang J;
PI Azimzai Y, Lu DAM, Au-Young J, Shih LL;
XX
DR MPI: 2001-016234/02.
DR P-PSDB: AAB36609.
XX
XX Human FLEXHT protein and DNA sequences, useful for treating
PT immunological disorders, developmental disorders, and cancers -
XX
PS Claim 5; Page 154; 168pp; English.
XX
XX AAC88070 to AAC88124 encode the 55 FLEXHT (full-length molecules
CC expressed in human tissues) proteins given in AAB36579 to AAB36633. The
CC present invention describes an isolated polypeptide (A) comprising an
CC amino acid sequence selected from one of 55 amino acid sequences 42-876
CC residues in length, corresponding to FLEXHT-1 to FLEXHT-55, a 90 %
CC identical sequence, and a biologically active or immunogenic fragment of
CC the sequence. The FLEXHT proteins can have antineutritic, anticonvulsant,
CC antiarteriosclerotic, immunomodulatory, cytostatic, antistaphylococcal,
CC antiinflammatory, hepatotropic, antidiabetic, anti-gout, antihypertensive,
CC neuroprotective, antiarthritic, osteopathic, antipsoriatic, anticancer
CC and antineutritic activities, and can be used in gene therapy. The
CC polynucleotide sequences can be used to express the protein sequences.
CC Pharmaceutical compositions comprising FLEXHT can be used to treat
CC diseases or conditions associated with altered expression of functional
CC FLEXHT. The proteins and polynucleotides can be used to diagnose and
CC treat disorders including anemia, epilepsy, arteriosclerosis,
CC atherosclerosis, developmental disorders, cancers, and immunological
CC disorders such as asthma, bronchitis, cirrhosis, Crohn's disease,
CC diabetes mellitus, gout, Grave's disease, multiple sclerosis,
CC osteoarthritis, pancreatitis, psoriasis, rheumatoid arthritis, and
CC ulcerative colitis.
XX
XX Sequence 1071 BP; 338 A; 190 C; 297 G; 246 T; 0 other;

Query Match	100.0%	Score 873:	DB 22:	Length 1071:
Best Local Similarity	100.0%	Pred. NO. 3.6e-221:		
Matches 873:	Conservative 0:	Mismatches 0:	Indels 0:	Gaps 0:
QY	1	tggagtgaggggtaacaagatgcgaccgagacgggtgagcttcctaagaagcttgc	60	
Db	165	tggagtgaggggtaacaagatgcgaccgagacgggtgagcttcctaagaagcttgc	224	
QY	61	cgaaactaaagcagaagatgcttgcctcggtgttggagaccaaagggaataagaagatct	120	
Db	225	cgaaactaaagcagaagatgcttgcctcggtgttggagaccaaagggaataagaagatct	284	
QY	121	tatccacagactccacgagcatctcttgaagaacatctcgaagagagagcacaatgaaaga	180	
Db	285	tatccacagactccacgagcatctcttgaagaacatctcgaagagagagcacaatgaaaga	344	
QY	161	tgtactgtagagtgtaaacagagagaagaagaacaaagcccatctgagctccctgtcaaga	240	
Db	345	tgtactgtagagtgtaaacagagagaagaagaacaaagcccatctgagctccctgtcaaga	404	
QY	241	ggaagaacccccctgtaaaaaaacctctgtgattggaagacagagaagaagatggtgaatatgc	300	
Db	405	ggaagaacccccctgtaaaaaaacctctgtgattggaagacagagaagaagatggtgaatatgc	464	
QY	301	atctgaatatcacacagactgtagagaatgcaagaagaagggtctgaacgattcaatgtacctgt	360	
Db	465	atctgaatatcacacagactgtagagaatgcaagaagaagggtctgaacgattcaatgtacctgt	524	
QY	361	gagccttgagagtaagaaagcgtccctcgagcaataagtttggaattcttcagttccaac	420	
Db	525	gagccttgagagtaagaaagcgtccctcgagcaataagtttggaattcttcagttccaac	584	
QY	421	aaaaggtcgtcatctgtataacaacactgtgttctaactggaataagctgaagaagaagac	480	

Db	585	aaaagctctgcacatcgataacaacactatggttaacttgataaagctgaaggaaaagc	644
Qy	481	lcaaaagatttgcttgaatgctctcctcaatctccagaagaagtcgtgaagatgagaact	540
Db	645	lcaaaagatttgcttgaatgctctcctcaatctccagaagaagtcgtgaagatgagaact	704
Qy	541	gaaaaagaggagaagcgatttggatgtgcacaagtgcagctggagactggaaaccaaga	600
Db	705	gaaaaagaggagaagcgatttggatgtgcacaagtgcagctggagactggaaaccaaga	764
Db	765	gatacagagcgcaagaagagaagaagagcagcgcttggattgctgttgtaaaagt	824
Qy	661	tcctgatctcttcgtcttcctccagtgcttccattctcctctctctgtgccaatata	720
Db	825	tcctgatctcttcgtcttcctccagtgcttccattctcctctctctgtgccaatata	884
Qy	721	tgccctaaatgcacagctcatgctgcttaagtcctgcctccgaatgagggaagcatcccca	780
Db	885	tgccctaaatgcacagctcatgctgcttaagtcctgcctccgaatgagggaagcatcccca	944
Qy	781	ggtacatccatgatgaactcgcgcgacgagcttgactattgcttgcttcaagcttaagttgt	840
Db	945	ggtacatccatgatgaactcgcgcgacgagcttgactattgcttgcttcaagcttaagttgt	1004
Qy	841	gtgtttgtgttttgattgattgtgctgttaat	873
Db	1005	gtgtttgtgttttgattgattgtgctgttaat	1037
RESULT 2			
AAS29109			
ID	AAS29109 standard; cDNA, 1154 BP.		
XX	AAS29109;		
AC			
XX			
DT	21-NOV-2001 (first entry)		
XX			
DE	cDNA encoding for human DNA-binding protein #80.		
XX			
KW	Human; DNA-binding protein; histone; chromo domain protein;		
KW	chromatin organisation modifier; Y-box binding protein;		
KW	DNA organisation; gene transcription; malignant disease;		
KW	autoimmune disorder; rheumatic disease; genetic abnormality;		
KW	infectious disease; neurological disorder; gene therapy;		
KW	immunomodulatory; anti-HIV; anti rheumatic; anti microbial;		
KW	cyostatic; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200155162-A1.		
XX			
PD	02-AUG-2001.		
XX			
PF	17-JAN-2001; 2001MO-US01305.		
XX			
XX			
PR	31-JAN-2000; 2000US-0179065.		
PR	04-FEB-2000; 2000US-0180628.		
PR	24-FEB-2000; 2000US-0184664.		
PR	02-MAR-2000; 2000US-0186350.		
PR	16-MAR-2000; 2000US-0189874.		
PR	17-MAR-2000; 2000US-0190076.		
PR	18-APR-2000; 2000US-0198123.		
PR	19-MAY-2000; 2000US-0205515.		
PR	07-JUN-2000; 2000US-0209467.		
PR	28-JUN-2000; 2000US-0214886.		
PR	30-JUN-2000; 2000US-0215135.		
PR	07-JUL-2000; 2000US-0216647.		
PR	07-JUL-2000; 2000US-0216880.		
PR	11-JUL-2000; 2000US-0217487.		
PR	11-JUL-2000; 2000US-0217496.		

PR	14-JUL-2000	2000US-0218290
PR	26-JUL-2000	2000US-0220963
PR	14-AUG-2000	2000US-0220964
PR	14-AUG-2000	2000US-0224518
PR	14-AUG-2000	2000US-0224519
PR	14-AUG-2000	2000US-0225213
PR	14-AUG-2000	2000US-0225214
PR	14-AUG-2000	2000US-0225266
PR	14-AUG-2000	2000US-0225267
PR	14-AUG-2000	2000US-0225268
PR	14-AUG-2000	2000US-0225270
PR	14-AUG-2000	2000US-0225447
PR	14-AUG-2000	2000US-0225757
PR	14-AUG-2000	2000US-0225758
PR	14-AUG-2000	2000US-0225759
PR	14-AUG-2000	2000US-0226279
PR	18-AUG-2000	2000US-0226284
PR	22-AUG-2000	2000US-0226681
PR	22-AUG-2000	2000US-0226686
PR	22-AUG-2000	2000US-0227182
PR	23-AUG-2000	2000US-0227189
PR	30-AUG-2000	2000US-0228294
PR	01-SEP-2000	2000US-0228287
PR	01-SEP-2000	2000US-0228343
PR	01-SEP-2000	2000US-0228344
PR	01-SEP-2000	2000US-0228345
PR	05-SEP-2000	2000US-0228509
PR	05-SEP-2000	2000US-0228513
PR	06-SEP-2000	2000US-0230437
PR	06-SEP-2000	2000US-0230438
PR	08-SEP-2000	2000US-0231242
PR	08-SEP-2000	2000US-0231244
PR	08-SEP-2000	2000US-0231413
PR	08-SEP-2000	2000US-0231414
PR	08-SEP-2000	2000US-0232080
PR	08-SEP-2000	2000US-0232081
PR	12-SEP-2000	2000US-0231968
PR	14-SEP-2000	2000US-0233397
PR	14-SEP-2000	2000US-0233398
PR	14-SEP-2000	2000US-0233399
PR	14-SEP-2000	2000US-0233400
PR	14-SEP-2000	2000US-0233401
PR	14-SEP-2000	2000US-0233064
PR	14-SEP-2000	2000US-0233065
PR	21-SEP-2000	2000US-0233263
PR	21-SEP-2000	2000US-0234274
PR	25-SEP-2000	2000US-0234997
PR	25-SEP-2000	2000US-0234998
PR	26-SEP-2000	2000US-0234984
PR	27-SEP-2000	2000US-0235834
PR	27-SEP-2000	2000US-0235837
PR	29-SEP-2000	2000US-0235367
PR	29-SEP-2000	2000US-0235368
PR	29-SEP-2000	2000US-0235369
PR	29-SEP-2000	2000US-0235370
PR	02-OCT-2000	2000US-0236802
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237039
PR	13-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239355
PR	13-OCT-2000	2000US-0239357
PR	20-OCT-2000	2000US-0241221
PR	20-OCT-2000	2000US-0241221
PR	20-OCT-2000	2000US-0241785
PR	20-OCT-2000	2000US-0241786
PR	20-OCT-2000	2000US-0241787
PR	20-OCT-2000	2000US-0241808
PR	20-OCT-2000	2000US-0241809
PR	01-NOV-2000	2000US-0244816
PR	01-NOV-2000	2000US-0244817

CC	08-NOV-2000; 2000US-0246474.
PR	08-NOV-2000; 2000US-0246475.
PR	08-NOV-2000; 2000US-0246476.
PR	08-NOV-2000; 2000US-0246477.
PR	08-NOV-2000; 2000US-0246478.
PR	08-NOV-2000; 2000US-0246523.
PR	08-NOV-2000; 2000US-0246524.
PR	08-NOV-2000; 2000US-0246525.
PR	08-NOV-2000; 2000US-0246526.
PR	08-NOV-2000; 2000US-0246527.
PR	08-NOV-2000; 2000US-0246528.
PR	08-NOV-2000; 2000US-0246532.
PR	08-NOV-2000; 2000US-0246609.
PR	08-NOV-2000; 2000US-0246610.
PR	08-NOV-2000; 2000US-0246611.
PR	08-NOV-2000; 2000US-0246613.
PR	17-NOV-2000; 2000US-0246207.
PR	17-NOV-2000; 2000US-0248208.
PR	17-NOV-2000; 2000US-0249209.
PR	17-NOV-2000; 2000US-0249210.
PR	17-NOV-2000; 2000US-0249211.
PR	17-NOV-2000; 2000US-0249212.
PR	17-NOV-2000; 2000US-0249213.
PR	17-NOV-2000; 2000US-0249214.
PR	17-NOV-2000; 2000US-0249215.
PR	17-NOV-2000; 2000US-0249216.
PR	17-NOV-2000; 2000US-0249217.
PR	17-NOV-2000; 2000US-0249218.
PR	17-NOV-2000; 2000US-0249219.
PR	17-NOV-2000; 2000US-0249224.
PR	17-NOV-2000; 2000US-0249245.
PR	17-NOV-2000; 2000US-0249264.
PR	17-NOV-2000; 2000US-0249265.
PR	17-NOV-2000; 2000US-0249297.
PR	17-NOV-2000; 2000US-0249299.
PR	17-NOV-2000; 2000US-0249300.
PR	01-DEC-2000; 2000US-0250160.
PR	01-DEC-2000; 2000US-0250391.
PR	05-DEC-2000; 2000US-0251030.
PR	05-DEC-2000; 2000US-0251988.
PR	05-DEC-2000; 2000US-0256719.
PR	06-DEC-2000; 2000US-0251479.
PR	08-DEC-2000; 2000US-0251856.
PR	08-DEC-2000; 2000US-0251868.
PR	08-DEC-2000; 2000US-0251869.
PR	08-DEC-2000; 2000US-0251989.
PR	08-DEC-2000; 2000US-0251990.
PR	11-DEC-2000; 2000US-0254097.
XX	05-JAN-2001; 2001US-0255678.
PA	(HUMA-) HUMAN GENOME SCI INC.
PI	Rosen CA, Barash SC, Ruben SM;
XX	.
DR	WPI; 2001-465557/50.
DR	P-PSDB; AAU18233.
XX	
PT	Nucleic acid molecules encoding human secreted chromosomal binding
PT	proteins, used in preventing, treating or ameliorating a disorder, e.g
PT	Alzheimer's and Parkinson's diseases and cancers -
XX	
PS	Claim 4; SEQ ID No 90; 561pp; English.
XX	
CC	The present invention relates to the isolation of novel DNA-binding
CC	proteins (AAU18154-AAU18281), and cDNA and genomic sequences encoding
CC	for these proteins. DNA-binding proteins such as histones, chromo
CC	(chromatin organisation modifier) domain proteins, and Y-box binding
CC	proteins may contribute to diseases resulting from aberrant DNA
CC	organisation and/or gene transcription. The sequences of the invention
CC	are useful in screening assays to identify antagonists and/or agonists
CC	that may enhance or block activities mediated by DNA-binding proteins.
CC	Blockers of DNA-binding proteins may be useful in treating disorders
CC	such as malignant diseases (e.g. cancer), autoimmune disorders
CC	(e.g. diabetes mellitus), rheumatic diseases (e.g. rheumatoid

arthritis), genetic abnormalities (e.g. cystic fibrosis), infectious diseases (e.g. HIV) and neurological disorders (e.g. Alzheimer's disease). The polynucleotide sequences of the invention may also be used in gene therapy. AAS29030-AAS29157 represent cDNA sequences encoding for novel DNA-binding proteins.

Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/published_pat_sequences](http://wipo.int/pub/published_pat_sequences).

SQ Sequence 1154 BP; 394 A; 186 C; 291 G; 281 T; 2 other;

Query Match	100.0%	Score 873	DB 22	Length 1154
Best Local Similarly	100.0%	Pred. No. 3.7e-231		
Matches 873; Conservative	0	Mismatches	0	Gaps 0

[illegible]

Db 1022 gtgttttgttttgatactagtgtctgtaat 1054

RESULT 3

ID AAS62602 standard; cDNA; 891 BP

AC AAS62602;

DT 14-FEB-2002 (first entry)

DE CDNA sequence #389 encoding novel human secreted protein.

KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;
 KW immune deficiency disorder; blood disorder; inflammatory disorder;
 KW infectious disorder; gene therapy; antimicrobial; hepatotropic;
 KW immunosuppressive; antineutrotic; ss.

OS Homo sapiens.

PN WO200177291-A2

PD 18-OCT-2001.

PF 29-MAR-2001; 2001WO-US10485.

PR 06-APR-2000; 2000US-195604P.

PA (GEMY) GENETICS INST INC.

PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes SH, Resnick RJ;

XX

XX
XX

PT asthma, HIV and Crohn's disease -

PS Claim 1; Page 280; 391pp; English.

CC The present invention relates to the isolation of novel cDNA sequences
CC which encode human secreted proteins. The cDNA sequences have been
CC derived from a variety of human tissues. The invention also provides
CC a method for producing proteins from these polynucleotide sequences.
CC The proteins are useful for identifying compounds that modulate their
CC activity and production, and the cell is also useful for identifying
CC compounds that modulate expression of the polynucleotide sequences
CC encoding the secreted proteins. The sequences of the invention are
CC useful for treating diseases such as hyperproliferative disorders
CC (e.g. cancer), immune deficiency disorders (e.g. severe combined
CC immunodeficiency (SCID)), autoimmune disorders (e.g. multiple
CC sclerosis), blood disorders (e.g. thrombocytopenia), inflammatory
CC disorders (e.g. arthritis) and infectious disorders (e.g. hepatitis).
CC The polynucleotide sequences of the invention are also useful in gene
CC therapy. A5562214/A562838 represent the cDNA sequences of the
CC invention that encode for novel human secreted proteins.

Sequence 891 BP; 221 A; 224 C; 157 G; 289 T; 0 other;

Query Match	97.88;	Score 853.4;	DB 24;	Length 891;
Best Local Similarity	99.88;	Pred. No. 8.7e-226;		
Matches 865; Conservative	0;	Mismatches 1;	Indels 1;	Gaps 1;

OY	8	aagggttaacaagaatgtagcgaccggaagcgtgtgtagctccataagcctaagcttgcgcgaacta	67
	886	AAGGTTAAACAAGATGAGCGACCCAGACGGTGGAGGCTCCATTAAGCTCTTAAGCTTGGCCGAACATA	822
Db			
OY	68	aagcaagaatgctctgtccgtcgtgtcttgagagaccaaaggaataaagcaagatcttatccac	127
	826	AAGCAAGAATGCTCTGTCTCGTGTGGTGGAGACCAAGGAATTAAGCAAGATCTTATCCAC	767
Db			

128 agactccagcgcatactcttgaagaacatgctgaagaagagagcgaatgaagaagatgtactg 187
Db AGACTCCAGCGCATCTTTGAAGAACATGCTGAAGAGAGGACCAATGAAGATGTACTG 707
Qy 188 ggaatgaagaagaggaagaagaacccattggcctccctgtctaaagaggaagaa 247
Db 706 ggaatgaagaagaggaagaagaacccattggcctccctgtctaaagaggaagaa 647
Qy 248 ccccttgaagaacatgttgaatgtgcaagagaagaagcgtgtaaaatattacatctga 307
Db 646 ccccttgaagaacatgttgaatgtgcaagagaagaagcgtgtaaaatattacatctga 587
Qy 308 ataccacagactgagagaatgcagaagaagggctgaacgattcaatgtaccgtgtgacttg 367
Db 586 ATACCACAGACTGAGAGAATGCAGAAAGAGGCTGAACGATTCAATGTACTGTGAGCTTG 527
Qy 368 gaggtgaagaagctgtctcggcagctaggtttggatttcttcaagtcacaacaaagt 427
Db 526 GAGAGTAAGAAAGCTGCTGGGAGCTAGGTTGGGATTTTTCAGTTCCAAACAAAGGT 467
Qy 428 ctgtcatctgtaacaacactatgttaacttgataagcgtgaaggaagagctcaaga 487
Db 466 CTGTCATCTGTATCAAAACCTATGTTACTTGATTAAGCTGAAGGAAAGAGCTCAAGA 407
Qy 488 ttggcttgaatgtctcttcaatctccagaagctgaaga tgaatgaagaactgaagaag 547
Db 406 TTGGCTTGAATGTCTCTTCAATCTCCAGAAAGTCTGAAGATGATGAAGAACTGAAGAA 347
Qy 548 aggaagaagcgaatttggatgtgcacaagctcagctgaac-tggaaccaagagatac 606
Db 346 AGGAAGAGCGATTGGATTGTCAACAGTTGACCTGGAACCTTGGAACCAAGAGATAC 287
Qy 607 agaagcaagaagaagaagaagcagcagcttgggaatgctcgaatgaagaagctcga 666
Db 286 AGAGCGCAAGAAAGAGAAAGAGAGAGCGCTTTGGGATTTCCCTGATATAAGTTCCCTGA 227
Qy 667 tacttctgtctccagctgtttccattctctccttcttcttctgtgcacatatgtccta 726
Db 226 TACTTTCTGTTCTCCAGTGTCTTCATTTCTCTCTCTCTGTGTCATATATAGCCTA 167
Qy 727 aatgcacagctatgtgcttaagctcgtcgtcgtcgaatgaggaagcagctgaacccaggtaca 786
Db 166 AATGCACAGCTATGTGCTTACGCTCGCTGCAATGAGGAGCATGATACCCCAAGTACA 107
Qy 787 tccatgaactcggcagcagcttgaactatgtcgtgttcagacttaagctgtgtgtt 846
Db 106 TCCATGAACCTCGGACAGAGTTTGACTTATGCTGTTTCACTTTAAGGTTGTGTGTTT 47
Qy 847 ttgttttgaatagctgtgtgtat 873
Db 46 TTGTTTGTATGTTGCTTGTAAAT 20

RESULT 4
AAC00738 standard; cDNA; 471 BP.
ID AAC00738:
AAC00738:
XX 06-OCT-2000 (first entry)
XX Human secreted protein 5' EST, SEQ ID NO: 736.
DE Human secreted protein 5' EST, SEQ ID NO: 736.
XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX Homo sapiens.
XX EPI03401-A2.
XX 06-SEP-2000.
XX 21-FEB-2000; 2000EP-0200610.
PF

XX 26-FEB-1999; 99US-0122487.
PR (GEST) GENSET.
XX Dumas Milne Edwards J, Duclert A, Giordano J;
PI WPI: 2000-500381/45.
XX P-PSDB; AAG00732.
DR New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
PS Claim 1; SEQ ID 736; 71pp + CD-ROM; English.
XX The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. An ORF has been identified within the
CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
CC derived from 30 different tissues. EST sequences usually correspond
CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC well suited for isolating cDNA sequences derived from the 5' ends of
CC mRNAs and even in those cases where longer cDNA sequences have been
CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
CC mRNAs with intact 5' ends and can therefore be used to obtain full length
CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
CC gene therapy and chromosome mapping procedures. They are used to obtain
CC upstream regulatory sequences and to design expression and secretion
CC vectors.
XX Sequence 471 BP; 165 A; 81 C; 130 G; 94 T; 1 other;
SQ

Query Match 53.3%; Score 465.6; DB 21; Length 471;
Best Local Similarity 99.8%; Pred. No. 1e-118;
Matches 465; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 tgaatgaggggttaacaagatgagcagcagaaggttgaagctccataagcctaaagctgc 60
Db 6 tgaatgaggggttaacaagatgagcagcagaaggttgaagctccataagcctaaagctgc 65
Qy 61 cgaactaagaagaatgtctgtcgtgtgttggagccaaaggaataaagcaagatct 120
Db 66 cgaactaagaagaatgtctgtcgtgtgttggagccaaaggaataaagcaagatct 125
Qy 121 taccacagactccagcatalcttgaagaacatgtctgaagaaggagcgaatgaaga 180
Db 126 taccacagactccagcatalcttgaagaacatgtctgaagaaggagcgaatgaaga 185
Qy 181 tgaatgaggggttaacaagatgagcagcagaaggttgaagctccataagcctaaagctgc 240
Db 186 tgaatgaggggttaacaagatgagcagcagaaggttgaagctccataagcctaaagctgc 245
Qy 241 ggaagaacccctgaaanaactgttgaatgtgcaagcagaagaagaagcgtgtaaaatc 300
Db 246 ggaagaacccctgaaanaactgttgaatgtgcaagcagaagaagaagcgtgtaaaatc 305
Qy 301 atctgaataaccacagactgagagaatgcagaagaagggtctgaacgattcaatgtactgt 360
Db 306 atctgaataaccacagactgagagaatgcagaagaagggtctgaacgattcaatgtactgt 365
Qy 361 gagcttgaagagtaagaagcgtgcgcggcagcgtggtttggatttcttaagttccaac 420
Db 366 gagcttgaagagtaagaagcgtgcgcggcagcgtggtttggatttcttaagttccaac 425
Qy 421 aaaagctgtcatctgaatacaaacctatgttgaactgtgaag 466
Db 426 aaaagctgtcatctgaatacaaacctatgttgaactgtgaag 471

RESULT 5
AAH81555

XX	AAH81555 standard; DNA; 408 BP.
XX	
AC	AAH81555;
XX	
DT	21-SEP-2001 (first entry)
XX	
DE	Human differential transcription-associated CDNA SEQ ID 64.
XX	
XX	Differential transcription; human; rat; tumour cell; cytostatic;
KW	Ras modulator; Class II tumour suppressor gene; gene therapy; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200157058-A2.
XX	
PD	09-AUG-2001.
XX	
PF	31-JAN-2001; 2001WO-EP01003.
XX	
PR	31-JAN-2000; 2000DE-1004102.
XX	
PA	(META-) METAGEN GES GENOMFORSCHUNG MBH.
XX	
PI	Rosenthal A, Hinzmann B, Schaefer R, Zuber J, Tchernitsa O;
PI	Grips M, Hellriegel M, Schmitz A, Sers C;
DR	WPI; 2001-483415/52.
PT	Nucleic acids differentially expressed between tumor and normal cells,
PT	useful for diagnosis or therapy of tumors and for screening active
PT	agents
XX	
PS	Disclosure; Page 350; 579pp; German.
XX	
CC	This invention describes a nucleic acid (I) with differential expression
CC	between tumour and normal cells and which has cytostatic activity. (I)
CC	work as modulators of Ras activity by inducing expression of tumour
CC	suppressor genes. (I), and polypeptides encoded by them, are useful as
CC	targets for diagnosis or therapy and in screening to determine the
CC	effects of an active compound (potential pharmaceutical) on a cell line,
CC	particularly for diagnosis and treatment of tumors, especially by
CC	modulating expression of (I) (by gene therapy, antisense RNA or ribozyme
CC	methods) or by modulating the amount and/or location of (I)-encoded
CC	polypeptides (by administration of the polypeptide or its activator,
CC	antibody (optionally as a conjugate) or inhibitor). The method allows
CC	identification of many Class II tumour suppressor genes (i.e. genes that
CC	are not primary targets for tumour-initiating mutations).
CC	AAH8192-AAH8236 represent the human and rat derived nucleic acid
CC	fragments described in the method of the invention.
XX	
50	Sequence 408 BP; 141 A; 66 C; 111 G; 88 T; 2 other;

Query Match	38.3%	Score 334	DB 822	Length 408
Best Local Similarity	98.0%	Prism No. 2.2e-82		
Matches 400	Conservative 0	Mismatches 2	Indels 6	Gaps 6
QY	185	ctggagagatgaacaagagaaagaagaacccattgagctccctgtccaagaagga	244	
Db	1	ctggagagatgaacaagagaaagaagaacccattgagctccctgtccaagaagga	60	
QY	245	gaacccctgaaaaaactcttgatctggcagagagaagaagaagtgtgtaaatcaact	304	
Db	61	gaacccctgaaaaaactcttgatctggcagagagaagaagaagtgtgtaaatcaact	120	
QY	305	gaatataccacagactggagagaatctgaagaagaagctcgaaacgtatcaatgtacgtgac	364	
Db	121	gaatataccacagactggagagaatctgaagaagaagctcgaaacgtatcaatgtacgtgac	180	
QY	365	ttggagaglaaagaagctgtctggcgacgtatggtttggattctctcaattccaacaana	424	
Db	181	ttggagaglaaagaagctgtctggcgacgtatggtttggattctctcaattccaacaana	240	

Qy	425	ggtcgtcatcttgatacaacaactatggttaactt- ggataagctggaaggaagctt-c	482
Db	241	ggtcgtcatcttgatacaacaactatggttaactt- ggataagctggaaggaagctt-c	300
Qy	463	aagatttggttgatgctcttcacatctccagaagtc- tgaagatgatga- gaact	540
Db	301	aagatttggttgatgctcttcacatctccagaagtc- tgaagatgatga- gaact	360
Qy	541	gaaagaaga-ggaagagagcagattt-gggatgtgcacaagttcagcttga 586	
Db	361	gaaagaagaggaagagcagatttggggattgttcacaagttcagcttga 408	
RESULT 6			
AL37635/c			
ID	AL37635	standard; DNA; 5469 BP.	
XX	AC	AL37635;	
XX	DT	08-JAN-2002 (first entry)	
DE	Human musculoskeletal system related polynucleotide SRQ ID NO 4000.		
XX			
KW	Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;		
KW	antiallergic; hepatotropic; antidiabetic; antinflammatory; antitumor;		
KW	vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;		
KW	cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;		
KW	neurological disease; infection; human; secreted protein;		
KW	musculoskeletal system; ds.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200155367-A1.		
XX			
PD	02-AUG-2001.		
XX			
PF	17-JAN-2001; 2001WO-US01338.		
XX			
PR	31-JAN-2000;	2000US-0179065.	
PR	04-FEB-2000;	2000US-0180628.	
PR	24-FEB-2000;	2000US-0184664.	
PR	02-MAR-2000;	2000US-0186350.	
PR	16-MAR-2000;	2000US-0189874.	
PR	17-MAR-2000;	2000US-0190076.	
PR	18-APR-2000;	2000US-0198123.	
PR	19-MAY-2000;	2000US-0205515.	
PR	07-JUN-2000;	2000US-0209467.	
PR	28-JUN-2000;	2000US-0214886.	
PR	30-JUN-2000;	2000US-0215135.	
PR	07-JUL-2000;	2000US-0216647.	
PR	07-JUL-2000;	2000US-0216880.	
PR	11-JUL-2000;	2000US-0217487.	
PR	11-JUL-2000;	2000US-0217496.	
PR	14-JUL-2000;	2000US-0218290.	
PR	26-JUL-2000;	2000US-0220963.	
PR	26-JUL-2000;	2000US-0220964.	
PR	14-AUG-2000;	2000US-0224518.	
PR	14-AUG-2000;	2000US-0224519.	
PR	14-AUG-2000;	2000US-0225213.	
PR	14-AUG-2000;	2000US-0225214.	
PR	14-AUG-2000;	2000US-0225266.	
PR	14-AUG-2000;	2000US-0225267.	
PR	14-AUG-2000;	2000US-0225268.	
PR	14-AUG-2000;	2000US-0225270.	
PR	14-AUG-2000;	2000US-0225277.	
PR	14-AUG-2000;	2000US-0225347.	
PR	14-AUG-2000;	2000US-0225758.	
PR	14-AUG-2000;	2000US-0225759.	
PR	18-AUG-2000;	2000US-0226279.	
PR	22-AUG-2000;	2000US-0226681.	
PR	22-AUG-2000;	2000US-0226688.	
PR	22-AUG-2000;	2000US-0227182.	
PR	23-AUG-2000;	2000US-0227009.	

PR	30- AUG- 2000	2000US-02298924
PR	01-SEP-2000	2000US-02292867
PR	01-SEP-2000	2000US-02292943
PR	01-SEP-2000	2000US-02292944
PR	01-SEP-2000	2000US-02292945
PR	05-SEP-2000	2000US-02295109
PR	05-SEP-2000	2000US-02295113
PR	06-SEP-2000	2000US-0230437
PR	06-SEP-2000	2000US-0230438
PR	08-SEP-2000	2000US-0231142
PR	08-SEP-2000	2000US-0231143
PR	08-SEP-2000	2000US-0231144
PR	08-SEP-2000	2000US-0231113
PR	08-SEP-2000	2000US-0231114
PR	08-SEP-2000	2000US-0232080
PR	08-SEP-2000	2000US-0232081
PR	12-SEP-2000	2000US-0231968
PR	14-SEP-2000	2000US-0232927
PR	14-SEP-2000	2000US-0232938
PR	14-SEP-2000	2000US-0232939
PR	14-SEP-2000	2000US-0232400
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0233063
PR	14-SEP-2000	2000US-0233064
PR	14-SEP-2000	2000US-0233065
PR	21-SEP-2000	2000US-0234422
PR	21-SEP-2000	2000US-0234472
PR	21-SEP-2000	2000US-0234473
PR	25-SEP-2000	2000US-0234997
PR	25-SEP-2000	2000US-0234998
PR	26-SEP-2000	2000US-0235484
PR	27-SEP-2000	2000US-0235534
PR	27-SEP-2000	2000US-0235536
PR	29-SEP-2000	2000US-0236127
PR	29-SEP-2000	2000US-0236167
PR	29-SEP-2000	2000US-0236368
PR	29-SEP-2000	2000US-0236370
PR	29-SEP-2000	2000US-0236579
PR	02-OCT-2000	2000US-0236602
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237039
PR	02-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239335
PR	13-OCT-2000	2000US-0239337
PR	20-OCT-2000	2000US-0240608
PR	20-OCT-2000	2000US-0241182
PR	20-OCT-2000	2000US-0241185
PR	20-OCT-2000	2000US-0241786
PR	01-NOV-2000	2000US-0246474
PR	08-NOV-2000	2000US-0246477
PR	08-NOV-2000	2000US-0246475
PR	08-NOV-2000	2000US-0246476
PR	08-NOV-2000	2000US-0246477
PR	08-NOV-2000	2000US-0246478
PR	08-NOV-2000	2000US-0246523
PR	08-NOV-2000	2000US-0246524
PR	08-NOV-2000	2000US-0246525
PR	08-NOV-2000	2000US-0246526
PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246528
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246539
PR	08-NOV-2000	2000US-0246610
PR	08-NOV-2000	2000US-0246611
PR	08-NOV-2000	2000US-0246613
PR	17-NOV-2000	2000US-0249207
PR	17-NOV-2000	2000US-0249208
PR	17-NOV-2000	2000US-0249209
PR	17-NOV-2000	2000US-0249210

Sequence Listing: English.

Example 2: SEQ ID NO 4000; 781pp + Sequence Listing: English.

The invention relates to novel genes (AAL34669-AAL37666) and proteins (ABR03087-ABR04109) associated with the musculoskeletal system useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. The genes are isolated from a range of human tissues disclosed in the specification. The nucleic acids, proteins, antibodies and (antagonists are useful in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c) cardiovascular disorders such as myocardial ischaemia; (d) wound healing; (e) neurological diseases e.g. cerebral anaemia and epilepsy; and (f) infectious diseases such as viral, bacterial, fungal and parasitic infections.

Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.

Sequence 5469 BP: 1793 A; 1119 C; 1201 G; 1356 T; 0 other;

Query Match	30.4%;	Score 265.4;	DB 22;	Length 5469;
Best Local Similarity	99.68;	Pred. No. 6.5e-63;		
Matches 266;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy 607 agagcacaagaagaggaagaagcagcgcttggatgtcctga tgaagaatctctga 666
 | | | | |
 Db 4965 ACAGGCAAGAGAGGAAAAGAGCAGCGCCTTGGGATTCCTGATGA AAAAGCTTCCTGA 4906

Oy	667	tactttctgtctccagtggttttccatttctctcccttcttctgtgtcaacataatagccta	726
Db	4905	TACTTTCTGTTCTCCAGTGTGTTTCCATTCTCTCCCTTTCTTGTGGCACATATATAGCCTA	4846
Oy	727	aatcacagtcacatbtgtcctacgtccgcctgcgaatgagagacatgtaacccagatgaca	786
Db	4845	AATCACAGTCACATGTGCTGCTACGTCTCGCTCGCAATGAGGAGACATATATAGCCTACA	4786
Oy	787	tccatgaactgcggcgcagcagtttgacttattgtctgtttcagctttaaaggtgtgtgtt	846
Db	4785	TCCATGACGACGCGGCACACATTTTGACTTATGCTGTTCAGCTTAAAGTGTGTGT	4726
Oy	847	ttgttttgatattgtgtcgtgttaat	873
Db	4725	TTGTTTTGATATATGTTGCTGTGTAAAT	4699
RESULT 7			
ABA08022/c			
ID	ABA08022 standard; DNA; 5469 BP.		
XX	ABA08022;		
AC			
XX			
DT	11-JAN-2002 (first entry)		
DE	Human ovarian and breast cancer associated polynucleotide seq ID NO 817.		
XX			
KW	Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;		
KW	antiallergic; hepatotropic; antidiabetic; antiinflammatory; antifucic;		
KW	vulnerable; anticonvulsant; antibacterial; antitumoral; antiparasitic;		
KW	cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;		
XX	neurological disease; infection; human; secreted protein; ds.		
OS	Homo sapiens.		
PN	MO200155325-A2.		
XX			
PD	02-AUG-2001.		
XX			
PF	17-JAN-2001; 2001MO-US01345.		
XX			
PR	31-JAN-2000;	2000US-0179065.	
PR	04-FEB-2000;	2000US-0180628.	
PR	24-FEB-2000;	2000US-0184664.	
PR	02-MAR-2000;	2000US-0186350.	
PR	16-MAR-2000;	2000US-0189874.	
PR	17-MAR-2000;	2000US-0190076.	
PR	18-APR-2000;	2000US-0198123.	
PR	19-MAY-2000;	2000US-0205515.	
PR	07-JUN-2000;	2000US-0209467.	
PR	28-JUN-2000;	2000US-0214886.	
PR	30-JUN-2000;	2000US-0215135.	
PR	07-JUL-2000;	2000US-0216647.	
PR	07-JUL-2000;	2000US-0216880.	
PR	11-JUL-2000;	2000US-0217487.	
PR	11-JUL-2000;	2000US-0217496.	
PR	14-JUL-2000;	2000US-0218290.	
PR	26-JUL-2000;	2000US-0220963.	
PR	26-JUL-2000;	2000US-0220964.	
PR	14-AUG-2000;	2000US-0224518.	
PR	14-AUG-2000;	2000US-0224519.	
PR	14-AUG-2000;	2000US-0225413.	
PR	14-AUG-2000;	2000US-0225414.	
PR	14-AUG-2000;	2000US-0225419.	
PR	14-AUG-2000;	2000US-0225447.	
PR	14-AUG-2000;	2000US-0225477.	
PR	14-AUG-2000;	2000US-0225757.	
PR	14-AUG-2000;	2000US-0225758.	
PR	14-AUG-2000;	2000US-0225759.	
PR	18-AUG-2000;	2000US-0226279.	
PR	22-AUG-2000;	2000US-0226681.	

PR	22-AUG-2000	2000US-0226686
PR	22-AUG-2000	2000US-0227182
PR	23-AUG-2000	2000US-0227709
PR	30-AUG-2000	2000US-0228924
PR	01-SEP-2000	2000US-0229287
PR	01-SEP-2000	2000US-0229434
PR	01-SEP-2000	2000US-0229444
PR	01-SEP-2000	2000US-0229395
PR	05-SEP-2000	2000US-0229513
PR	05-SEP-2000	2000US-0230438
PR	06-SEP-2000	2000US-0230437
PR	06-SEP-2000	2000US-0230438
PR	08-SEP-2000	2000US-0231142
PR	08-SEP-2000	2000US-0231143
PR	08-SEP-2000	2000US-0231144
PR	08-SEP-2000	2000US-0231145
PR	08-SEP-2000	2000US-0231143
PR	08-SEP-2000	2000US-0231144
PR	14-SEP-2000	2000US-0232398
PR	14-SEP-2000	2000US-0232399
PR	14-SEP-2000	2000US-0232400
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0233063
PR	14-SEP-2000	2000US-0233064
PR	14-SEP-2000	2000US-0233065
PR	21-SEP-2000	2000US-0234423
PR	21-SEP-2000	2000US-0234427
PR	21-SEP-2000	2000US-0234974
PR	25-SEP-2000	2000US-0235497
PR	25-SEP-2000	2000US-0235498
PR	25-SEP-2000	2000US-0235499
PR	26-SEP-2000	2000US-0235634
PR	27-SEP-2000	2000US-0235634
PR	27-SEP-2000	2000US-0235636
PR	29-SEP-2000	2000US-0236327
PR	29-SEP-2000	2000US-0236367
PR	29-SEP-2000	2000US-0236368
PR	29-SEP-2000	2000US-0236570
PR	02-OCT-2000	2000US-0236602
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237039
PR	02-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239937
PR	13-OCT-2000	2000US-0239937
PR	20-OCT-2000	2000US-0240960
PR	20-OCT-2000	2000US-0241121
PR	20-OCT-2000	2000US-0241185
PR	20-OCT-2000	2000US-0241787
PR	20-OCT-2000	2000US-0241786
PR	20-OCT-2000	2000US-0241808
PR	20-OCT-2000	2000US-0241809
PR	20-OCT-2000	2000US-0241826
PR	01-NOV-2000	2000US-0244617
PR	08-NOV-2000	2000US-0246474
PR	08-NOV-2000	2000US-0246475
PR	08-NOV-2000	2000US-0246476
PR	08-NOV-2000	2000US-0246477
PR	08-NOV-2000	2000US-0246478
PR	08-NOV-2000	2000US-0246523
PR	08-NOV-2000	2000US-0246524
PR	08-NOV-2000	2000US-0246525
PR	08-NOV-2000	2000US-0246526
PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246528
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246609
PR	08-NOV-2000	2000US-0246610
PR	08-NOV-2000	2000US-0246611
PR	08-NOV-2000	2000US-0246613
PR	17-NOV-2000	2000US-0249207

XX	PA	(HUMA-) HUMAN GENOME SCI INC.
XX	PI	Rosen CA, Barash SC, Ruben SM;
XX	DR	WPI; 2001-488786/53.
XX	PT	New isolated ovarian and/or breast cancer related nucleic acids and
XX	PS	polypeptides, useful for diagnosing, treating and/or preventing human
XX	PP	diseases and disorders, particularly ovarian and/or breast cancer -
XX	PP	disclosure; SEQ ID NO 817; 577bp + Sequence Listing; English.
CC	CC	The invention relates to novel genes (ABA07454-ABA08224) and proteins
CC	CC	(ABAI0743-ABBI0980) useful for preventing, treating or ameliorating
CC	CC	medical conditions e.g. by protein or gene therapy. The genes are
CC	CC	isolated from a range of human tissues disclosed in the specification.
CC	CC	The nucleic acids, proteins, antibodies and (ant)agonists are useful
CC	CC	in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC	CC	and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC	CC	marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC	CC	(b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC	CC	hemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC	CC	colitis, multiple sclerosis, rheumatoid arthritis and ulcerative
CC	CC	colitis; (c) cardiovascular disorders such as myocardial ischaemias;
CC	CC	(d) wound healing; (e) neurological diseases e.g. cerebral anoxia; and
CC	CC	epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC	CC	and parasitic infections.
CC	CC	Note: The sequence data for this patent did not form part of the
CC	CC	printed specification, but was obtained in electronic format directly
CC	CC	from WIPO at ftp.wipo.int/pub/published_pctl_sequences.
XQ	XX	Sequence 5469 BP; 1793 A; 1119 C; 1201 G; 1356 T; 0 other;

Query Match	30.4%;	Score 265.4;	DB 22;	Length 5469;
Best Local Similarity	99.6%;	Pred. No. 6.5e-63;		
Matches 266;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

QY 607 agagggcaagaagagaaaagcagagcgcttgggattgctgaigaaagttcctga 666
+ |||||
Db 4965 ACACGGCAAGAGAGGAAAGAGCAGAGCGCTTTGGGATTGCTGTAGCAAAAGTTCTTGA 4966

OY	667	tactcttcgtctccagtgctttccaatctctctctctctcttggtcaacatatagctcta	726
Db	4905	TACTTTCTGTTTCCAGCTGTTTTCCATTTCTCTCCCTTTCTTTGGTGCACATTAAGCCTA	4846
OY	727	aatcacagatcatbgtgctctacgcctccgcctcgaatagaagagagcatgtaacccagatgaca	786
Db	4885	AATGCACAGTCATATGCTCTTACGCTCTGCTCCGCAATAGAGGAGCATATACCCAGGTACA	4786
OY	787	lccatlgacttcgagcagcagctttgacttaattgctgtttcagctttaaagtttgtttgctt	846
Db	4785	TCCATGAACGCGGCACACCACTTTGACATTAATGCTGTTTCAGCTTAAGSTTTGTGTGTT	4726
OY	847	ttgcttttgatatalbgtgcttgtaaat	873
Db	4725	TTGTTTTGATTATGTTGCTTTTAAT	699

RESULT	8	
AAI06683/C		
ID	AAI06683	standard; DNA: 5469 BP.
XX		
AC	AAI06683;	
XX		
DT	21-NOV-2001	(first entry)
XX		
DE	Human reproductive system related antigen DNA SEQ ID NO: 9371.	
XX		
KW	Human; reproductive system related antigen; reproductive system disorder;	
RV	cancer; gene therapy; ds.	
XX		
OS	Homo sapiens.	
XX		
PN	W020015320-A2.	
XX		
PD	02-AUG-2001.	
XX		
PE	17-JAN-2001;	2001WO-US01339.
XX		
PR	31-JAN-2000;	2000US-0179065.
PR	04-FEB-2000;	2000US-0180628.
PR	24-FEB-2000;	2000US-0184664.
PR	02-MAR-2000;	2000US-0186350.
PR	16-MAR-2000;	2000US-0189874.
PR	17-MAR-2000;	2000US-0190076.
PR	18-APR-2000;	2000US-0198123.
PR	19-MAY-2000;	2000US-0205115.
PR	07-JUN-2000;	2000US-0209467.
PR	28-JUN-2000;	2000US-0214886.
PR	30-JUN-2000;	2000US-0215135.
PR	07-JUL-2000;	2000US-0216647.
PR	07-JUL-2000;	2000US-0216880.
PR	11-JUL-2000;	2000US-0217487.
PR	11-JUL-2000;	2000US-0217496.
PR	14-JUL-2000;	2000US-0218290.
PR	26-JUL-2000;	2000US-0220963.
PR	26-JUL-2000;	2000US-0220964.
PR	14-AUG-2000;	2000US-0224518.
PR	14-AUG-2000;	2000US-0224519.
PR	14-AUG-2000;	2000US-0225213.
PR	14-AUG-2000;	2000US-0225214.
PR	14-AUG-2000;	2000US-0225266.
PR	14-AUG-2000;	2000US-0225267.
PR	14-AUG-2000;	2000US-0225268.
PR	14-AUG-2000;	2000US-0225270.
PR	14-AUG-2000;	2000US-0225447.
PR	14-AUG-2000;	2000US-0225758.
PR	14-AUG-2000;	2000US-0225759.
PR	18-AUG-2000;	2000US-0226279.
PR	22-AUG-2000;	2000US-0226681.
PR	22-AUG-2000;	2000US-0226682.
PR	22-AUG-2000;	2000US-0227182.

PR	23-AUG-2000	2000US-02227009
PR	30-AUG-2000	2000US-02228924
PR	01-SEP-2000	2000US-02229587
PR	01-SEP-2000	2000US-02229343
PR	01-SEP-2000	2000US-02229144
PR	01-SEP-2000	2000US-02229345
PR	03-SEP-2000	2000US-02229513
PR	05-SEP-2000	2000US-02229513
PR	06-SEP-2000	2000US-02304337
PR	06-SEP-2000	2000US-02304338
PR	08-SEP-2000	2000US-02320801
PR	08-SEP-2000	2000US-02313442
PR	08-SEP-2000	2000US-02312443
PR	08-SEP-2000	2000US-02312444
PR	08-SEP-2000	2000US-02313443
PR	08-SEP-2000	2000US-02314113
PR	08-SEP-2000	2000US-02313665
PR	21-SEP-2000	2000US-02342223
PR	21-SEP-2000	2000US-02342774
PR	25-SEP-2000	2000US-02345497
PR	25-SEP-2000	2000US-02344998
PR	26-SEP-2000	2000US-02351884
PR	27-SEP-2000	2000US-02358334
PR	27-SEP-2000	2000US-02333065
PR	27-SEP-2000	2000US-02335236
PR	29-SEP-2000	2000US-02363227
PR	29-SEP-2000	2000US-02363567
PR	29-SEP-2000	2000US-02363568
PR	29-SEP-2000	2000US-02363569
PR	29-SEP-2000	2000US-02366870
PR	02-OCT-2000	2000US-02370338
PR	02-OCT-2000	2000US-02370337
PR	02-OCT-2000	2000US-02370338
PR	02-OCT-2000	2000US-02370339
PR	02-OCT-2000	2000US-02370400
PR	13-OCT-2000	2000US-02399335
PR	13-OCT-2000	2000US-02399337
PR	20-OCT-2000	2000US-02418096
PR	20-OCT-2000	2000US-02418121
PR	20-OCT-2000	2000US-02418126
PR	01-NOV-2000	2000US-02445127
PR	08-NOV-2000	2000US-02464774
PR	08-NOV-2000	2000US-02464775
PR	08-NOV-2000	2000US-02464776
PR	08-NOV-2000	2000US-02464777
PR	08-NOV-2000	2000US-02464778
PR	08-NOV-2000	2000US-02464788
PR	08-NOV-2000	2000US-02465223
PR	08-NOV-2000	2000US-02465224
PR	08-NOV-2000	2000US-02465225
PR	08-NOV-2000	2000US-02465226
PR	08-NOV-2000	2000US-02465227
PR	08-NOV-2000	2000US-02465228
PR	08-NOV-2000	2000US-02465332
PR	08-NOV-2000	2000US-02466109
PR	08-NOV-2000	2000US-02466110
PR	08-NOV-2000	2000US-02466111
PR	17-NOV-2000	2000US-02494207
PR	17-NOV-2000	2000US-02494208
PR	17-NOV-2000	2000US-02494209

PR	17-NOV-2000;	2000US-0249210.
PR	17-NOV-2000;	2000US-0249211.
PR	17-NOV-2000;	2000US-0249212.
PR	17-NOV-2000;	2000US-0249213.
PR	17-NOV-2000;	2000US-0249214.
PR	17-NOV-2000;	2000US-0249215.
PR	17-NOV-2000;	2000US-0249216.
PR	17-NOV-2000;	2000US-0249217.
PR	17-NOV-2000;	2000US-0249218.
PR	17-NOV-2000;	2000US-0249219.
PR	17-NOV-2000;	2000US-0249220.
PR	17-NOV-2000;	2000US-0249221.
PR	17-NOV-2000;	2000US-0249222.
PR	17-NOV-2000;	2000US-0249223.
PR	17-NOV-2000;	2000US-0249224.
PR	17-NOV-2000;	2000US-0249225.
PR	17-NOV-2000;	2000US-0249226.
PR	17-NOV-2000;	2000US-0249227.
PR	17-NOV-2000;	2000US-0249228.
PR	17-NOV-2000;	2000US-0249229.
PR	17-NOV-2000;	2000US-0249300.
PR	01-DEC-2000;	2000US-0250160.
PR	01-DEC-2000;	2000US-0250391.
PR	05-DEC-2000;	2000US-0251030.
PR	05-DEC-2000;	2000US-0251988.
PR	05-DEC-2000;	2000US-0256719.
PR	06-DEC-2000;	2000US-0251479.
PR	08-DEC-2000;	2000US-0251856.
PR	08-DEC-2000;	2000US-0251868.
PR	08-DEC-2000;	2000US-0251869.
PR	08-DEC-2000;	2000US-0251983.
PR	08-DEC-2000;	2000US-0251990.
PR	11-DEC-2000;	2000US-0254097.
PR	05-JAN-2001;	2001US-0259678.
XX		
PA	(HUMA-)	HUMAN GENOME SCI INC.
XX		
PI	Rosen CA,	Barash SC, Ruben SM;
XX		
DR	WPI;	2001-465570/50.
XX		
PT	Isolated nucleic acid molecule encoding a reproductive system antigen -	
PT	is used in preventing, treating or ameliorating a medical condition -	
XX		
PS	Disclosure; SEQ ID NO 9371;	1297bp + Sequence Listing; English.
XX		
XX		
CC	The present invention provides the protein and coding sequences of a	
CC	number of human reproductive system related antigens. These can be used	
CC	in the prevention and treatment of reproductive system disorders,	
CC	including cancer. The present sequence is a genomic sequence encoding a	
CC	protein of the invention.	
XX		
SO	Sequence 5469 BP; 1793 A; 1119 C; 1201 G; 1356 T; 0 other;	

	Query Match	30.4%	Score 265.4	DB 22	Length 5469
	Best Local Similarity	99.6%	Pred. No. 8.5e-63		
	Matches 266	Conservative 0	Mismatches 1	Indels 0	Gaps 0
QY	607	agaagcaaaagaagaagaaaagacagcagcgcttcttggaattgcctatgataaagtcccta	666		
Dd	4965	ACAGGCAAAAGAAGAGAAAAGACAGAGCGCTTGGATTTGCCGTATGAAAAATTCCGA	4906		
QY	667	tacttcgtctccaaagtttccattctctctcttcttccttcttgtaacatatagcta	726		
Dd	4905	TACTTCGTCTTCCAGTGTTTTCCATTTCTCTCTTCTCTTGATGCATAATATGCTTA	4846		
QY	727	aatgacagctcatctgctcactgacctgcgaattgaggagacatgtaccacagtlaca	786		
Dd	4845	AATGCACAGTCATGTHGCTACGTCCTGCCTGCATGAGGGAGCATGTACCACAGTACA	4786		
QY	787	lccacgaactcggggagacagtttgacttatatgctgtttcacgtttaagtgttgttctt	846		
Dd	4785	TCCATGAACTCGGGAGCAGTTTGACTTAATTCCTGTTTCAGCTTTAAGGTTGTGTGTT	4726		
QY	847	ttgtcttcgatcatatgttgctgtaat	873		
Dd	4725	TTGTTTTGATTATGTTGCTTTTAT	4699		

RESULT 9
AAK84119/c
ID AAK84119 standard; DNA, 5469 BP.
XX
AC AAK84119;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:38931.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PE 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 14-JUL-2000; 2000US-0217496.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225256.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.

PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249254.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.

PR	08-SEP-2000	2000US-02320801
PR	08-SEP-2000	2000US-0232081
PR	12-SEP-2000	2000US-0231968
PR	14-SEP-2000	2000US-0232397
PR	14-SEP-2000	2000US-0232397
PR	14-SEP-2000	2000US-0232398
PR	14-SEP-2000	2000US-0232399
PR	14-SEP-2000	2000US-0232400
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0233063
PR	14-SEP-2000	2000US-0233064
PR	14-SEP-2000	2000US-0233065
PR	21-SEP-2000	2000US-0234223
PR	21-SEP-2000	2000US-0234272
PR	25-SEP-2000	2000US-0234997
PR	25-SEP-2000	2000US-0234998
PR	26-SEP-2000	2000US-0234584
PR	27-SEP-2000	2000US-0235334
PR	27-SEP-2000	2000US-0235627
PR	29-SEP-2000	2000US-0236127
PR	29-SEP-2000	2000US-0236167
PR	29-SEP-2000	2000US-0236168
PR	29-SEP-2000	2000US-0236599
PR	29-SEP-2000	2000US-0236570
PR	02-OCT-2000	2000US-0236502
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237040
PR	02-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239365
PR	13-OCT-2000	2000US-0239367
PR	20-OCT-2000	2000US-0241808
PR	20-OCT-2000	2000US-0241809
PR	20-OCT-2000	2000US-0241810
PR	20-OCT-2000	2000US-0241812
PR	20-OCT-2000	2000US-0241815
PR	20-OCT-2000	2000US-0241787
PR	20-OCT-2000	2000US-0241787
PR	08-NOV-2000	2000US-0246674
PR	08-NOV-2000	2000US-0246675
PR	08-NOV-2000	2000US-0246676
PR	08-NOV-2000	2000US-0246677
PR	08-NOV-2000	2000US-0246678
PR	08-NOV-2000	2000US-0246522
PR	08-NOV-2000	2000US-0246523
PR	08-NOV-2000	2000US-0246524
PR	08-NOV-2000	2000US-0246525
PR	08-NOV-2000	2000US-0246526
PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246528
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246509
PR	08-NOV-2000	2000US-0246510
PR	08-NOV-2000	2000US-0246611
PR	08-NOV-2000	2000US-0246612
PR	17-NOV-2000	2000US-0249211
PR	17-NOV-2000	2000US-0249212
PR	17-NOV-2000	2000US-0249213
PR	17-NOV-2000	2000US-0249214
PR	17-NOV-2000	2000US-0249215
PR	17-NOV-2000	2000US-0249216
PR	17-NOV-2000	2000US-0249217
PR	17-NOV-2000	2000US-0249218
PR	17-NOV-2000	2000US-0249219
PR	17-NOV-2000	2000US-0249244
PR	17-NOV-2000	2000US-0249245
PR	17-NOV-2000	2000US-0249264
PR	17-NOV-2000	2000US-0249265
PR	17-NOV-2000	2000US-0249266
PR	17-NOV-2000	2000US-0249267
PR	17-NOV-2000	2000US-0249268
PR	17-NOV-2000	2000US-0249269
PR	17-NOV-2000	2000US-0249270
PR	17-NOV-2000	2000US-0249271
PR	17-NOV-2000	2000US-0249272
PR	17-NOV-2000	2000US-0249273
PR	17-NOV-2000	2000US-0249274
PR	17-NOV-2000	2000US-0249275
PR	17-NOV-2000	2000US-0249276
PR	17-NOV-2000	2000US-0249277
PR	17-NOV-2000	2000US-0249278
PR	17-NOV-2000	2000US-0249279
PR	17-NOV-2000	2000US-0249280
PR	17-NOV-2000	2000US-0249281
PR	17-NOV-2000	2000US-0249282
PR	17-NOV-2000	2000US-0249283
PR	17-NOV-2000	2000US-0249284
PR	17-NOV-2000	2000US-0249285
PR	17-NOV-2000	2000US-0249286
PR	17-NOV-2000	2000US-0249287
PR	17-NOV-2000	2000US-0249288
PR	17-NOV-2000	2000US-0249289
PR	17-NOV-2000	2000US-0249290
PR	17-NOV-2000	2000US-0249291
PR	17-NOV-2000	2000US-0249292

17-NOV-2000; 2000US-0249300.
01-DEC-2000; 2000US-0250160.
01-DEC-2000; 2000US-0250391.
05-DEC-2000; 2000US-0251030.
05-DEC-2000; 2000US-0251988.
05-DEC-2000; 2000US-0256719.
06-DEC-2000; 2000US-0251479.
08-DEC-2000; 2000US-0251856.
08-DEC-2000; 2000US-0251868.
08-DEC-2000; 2000US-0251869.
08-DEC-2000; 2000US-0251989.
08-DEC-2000; 2000US-0251990.
11-DEC-2000; 2000US-0254097.
05-JAN-2001; 2001US-0259678.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-451937/48.
Isolated polypeptide for treating, preventing and/ or prognosing
disorders related to the musculoskeletal system including
musculoskeletal cancers and also for testing and detection e.g.
diagnosis -
Example 2; SEQ ID NO 3999; 781pp + Sequence Listing; English.
The invention relates to novel genes (AAL34669-AAL37666) and proteins
(ABB03087-ABB04109) associated with the musculoskeletal system useful
for preventing, treating or ameliorating medical conditions e.g. by
protein or gene therapy. The genes are isolated from a range of human
tissues disclosed in the specification. The nucleic acids, proteins,
antibodies and (ant)agonists are useful in the diagnosis, treatment
and prevention of: (a) cancer, e.g. breast and ovarian cancer and
other cancers of the adrenal gland, bone, bone marrow, breast,
gastrointestinal tract, liver, lung, or urogenital; (b) immune
disorders e.g. Addison's disease, allergies, autoimmune haemolytic
anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
(c) cardiovascular disorders such as myocardial ischaemia; (d) wound
healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy;
and (f) infectious diseases such as viral, bacterial, fungal and
parasitic infections.
Note: The sequence data for this patent did not form part of the
printed specification, but was obtained in electronic format directly
from WIPO at ftp.wipo.int/pub/published_pat_sequences.
Sequence 9453 BP; 2869 A; 2071 C; 2294 G; 2219 T; 0 other;

Query Match	30.4%	Score 265.4	DB 22	Length 9453
Best Local Similarity	99.6%	Fred. No. 8.4e-63		
Matches 266	Conservative	0	Mismatches 1	Indels 0
Qy 607	aaagagcaagaagagaaagagacagagcgcttggagttgcctgatataaagttcciga	666		
Db 8949	ACAGGCAAGAAGAGGAAAGACAGAGCGCTTTGGATTGCTTAATGAAGTTCTCGA	8890		
Qy 667	tactttcgttcctccagtgtttccatctctctctctctcttcttgtaacatatatgccta	726		
Db 8889	TACTTTCTGTTGTTCCAGTGTTTTTCATTCTCTCTCTCTCTTCTTGGTCAATATATGCCGA	8830		
Qy 727	aatgcacagtcatagtgctcactgcctgcctcgaaatgagggagcaatgtaacccagttaca	786		
Db 8829	AATGCACAGTCATGTGCTTACCTGCTGCTCCGCAATGAGGGAGCATGTACCCAGGTACA	8770		
Qy 787	tccatgaactcgtggagcagcttgcctattatgcttcttccagtttaagtttgttgtttc	846		
Db 8769	TCCATGAACTCGGGAGGACAGTTTGACTTAATGCTTTTTCAGCTTTAAAGGTTGTGTGTTT	8710		
Qy 847	ttgttttcgatattgttcgttgtaat	873		

Db 8709 TTGTTTTCATTATGTTGCTTCTTAAT 8683

RESULT 11
ABA08021/C
ID ABA08021 standard; DNA; 9453 BP.
XX
AC ABA08021;
XX
DT 11-JAN-2002 (first entry)
XX
DE Human ovarian and breast cancer associated polynucleotide SEQ ID NO 816.
XX
KW Cytostatic; immunosuppressive; noctropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antinflammatory; anticancer;
KW vulnerrary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein; ds.
XX
OS Homo sapiens.
XX
PN WO20015325-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01345.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225457.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.

PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0244675.
PR 08-NOV-2000; 2000US-0244676.
PR 08-NOV-2000; 2000US-0244677.
PR 08-NOV-2000; 2000US-0244678.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.

Thu Jun 20 13:15:20 2002

XX Homo sapiens.
OS
XX WO200157182-A2.
PN
XX 09-AUG-2001.
PD
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.

PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249267.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 06-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX

THIS PAGE BLANK (USPTO)